Articles related to TRANSPLANT MEDICINE

Continued collaboration across disciplines, enhanced focus on standardization, and investments in emerging technologies are imperative for bridging the gaps and driving innovation.

“We are surprised and disappointed by this FDA decision for EBV+ PTLD patients who have a significant unmet need, highlighted by tabelecleucel’s orphan drug designation and by the granting of breakthrough status.” — Dr. Cokey Nguyen, Atara CEO

“Although historically grouped together, viral-associated PCNSL subtypes are biologically distinct diseases. Each escapes immune control through a different mechanism, creating fundamentally different tumor microenvironments.” – Melinda Burgess, Researcher from the Department of Haematology at Princess Alexandra Hospital

Similar efficacy was observed in pediatric patients aged 12 years and older – demonstrating consistent treatment benefit across age groups in the pivotal trial.

“Mean LOS post-transplant was significantly shorter in the post-APP cohort (P = .005). The mean LOS for the pre- and post-APP cohorts were 22.4 and 16.5 days, respectively.”

Posttreatment dosimetric analysis demonstrated that higher specific activity microspheres overcome tumor heterogeneity by ensuring adequate radiation delivery throughout the entire tumor volume, particularly in poorly perfused regions.